(Reuters) - Johnson & Johnson beat expectations for quarterly earnings and raised its dividend payouts to shareholders on Tuesday, while reporting $100 million in sales of its COVID-19 vaccine, whose use was paused by U.S. regulators last week.
The company, which has previously said the vaccine will be available on a not-for-profit basis until the end of the pandemic, also tightened its forecast for adjusted profit this year, suggesting it was largely performing as previously expected.
Use of the company's vaccine was temporarily halted by U.S. regulators as they investigate reports of blood clots in six women, prompting a similar pause in South Africa and leading to a delay in rollout in Europe.
The United States is also reviewing a handful of potential cases of severe side effects in addition to those that led to the pause.
J&J is aiming to deliver 100 million doses of the vaccine to the United States before the end of May, of which more than 17 million have already been distributed as of Monday.
"While we expect many questions on its Covid-19 vaccine, this should not overshadow the strong recovery for J&J," Citi analyst Joanne Wuensch wrote in a note to clients.
Sales of cancer drug Darzalex rose 45.7% to $1.37 billion and sales of Stelara, a treatment for Crohn's disease and plaque psoriasis, rose about 18% to $2.15 billion.
The company now expects full-year adjusted profit of $9.42 to $9.57 per share, compared with its prior forecast of $9.40 to $9.60 per share.
Excluding items, the company earned $2.59 per share, beating analysts' estimates of $2.34 per share, according to IBES data from Refinitiv.
Total sales rose 7.9% to $22.32 billion, beating estimates of $21.98 billion.
The company also increased its quarterly dividend to $1.06 per share from $1.01 per share.
(Reporting by Manas Mishra and Manojna Maddipatla in Bengaluru; Editing by Anil D'Silva)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU